M
339.66
-11.04 (-3.15%)
| 前收盘价格 | 350.70 |
| 收盘价格 | 357.81 |
| 成交量 | 329,131 |
| 平均成交量 (3个月) | 345,684 |
| 市值 | 7,408,120,320 |
| 价格/销量 (P/S) | 91.48 |
| 股市价格/股市净资产 (P/B) | 9.51 |
| 52周波幅 | |
| 利润日期 | 31 Oct 2024 |
| 营业利益率 (TTM) | -187.06% |
| 稀释每股收益 (EPS TTM) | -25.05 |
| 总债务/股东权益 (D/E MRQ) | 15.33% |
| 流动比率 (MRQ) | 5.98 |
| 营业现金流 (OCF TTM) | -431.02 M |
| 杠杆自由现金流 (LFCF TTM) | -263.11 M |
| 资产报酬率 (ROA TTM) | -52.25% |
| 股东权益报酬率 (ROE TTM) | -129.76% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Madrigal Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 8.56% |
| 机构持股比例 | 105.84% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 441.00 (UBS, 29.84%) | 购买 |
| 中 | 400.00 (17.77%) | |
| 低 | 236.00 (B. Riley Securities, -30.52%) | 保留 |
| 平均值 | 370.80 (9.17%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 300.46 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Jan 2025 | 400.00 (17.76%) | 购买 | 303.71 |
| 22 Oct 2024 | 390.00 (14.82%) | 购买 | 203.59 | |
| JMP Securities | 10 Jan 2025 | 427.00 (25.71%) | 购买 | 338.91 |
| B. Riley Securities | 05 Nov 2024 | 236.00 (-30.52%) | 保留 | 337.61 |
| UBS | 01 Nov 2024 | 441.00 (29.84%) | 购买 | 319.58 |
| Oppenheimer | 23 Oct 2024 | 350.00 (3.04%) | 购买 | 202.48 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合